The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -25,540 |
| Allowance for credit losses (recoveries) | 21 |
| Depreciation and amortization | 814 |
| Amortization of intangible assets | 168 |
| Share-based compensation | 8,180 |
| Payment-in-kind interest | 908 |
| Amortization of debt issuance costs and original issue discounts | 83 |
| Amortization of lease right of use assets, net of accretion in lease liabilities | 1,255 |
| Accounts receivable | 268 |
| Inventory, net | 103 |
| Prepaid expenses and other current assets | 397 |
| Other assets | 195 |
| Accounts payable and accrued expenses | -7,520 |
| Lease liabilities | -1,012 |
| Contract liabilities | -319 |
| Net cash flows from operating activities | -23,925 |
| Cash acquired in business combination, net of cash paid | 1,137 |
| Purchases of property and equipment | 522 |
| Net cash flows from investing activities | 615 |
| Proceeds from offerings of common stock, net of offering costs | 3,263 |
| Proceeds from issuance of notes payable, net of financing costs and discount | 48,086 |
| Repayment of 2020 senior secured convertible note | 0 |
| Proceeds from stock option exercises | 127 |
| Payments for taxes related to net share settlement of equity awards | 1,856 |
| Proceeds from issuance of common stock under employee stock purchase plan | 559 |
| Net cash flows from financing activities | 50,179 |
| Net change in cash, cash equivalents and restricted cash | 26,869 |
| Cash, cash equivalents and restricted cash, beginning of year | 20,104 |
| Cash, cash equivalents and restricted cash, end of year | 46,973 |
ClearPoint Neuro, Inc. (CLPT)
ClearPoint Neuro, Inc. (CLPT)